Skip to main content
Erschienen in: Clinical and Translational Oncology 5/2013

01.05.2013 | Brief Research Article

Cone-beam computed tomography dose monitoring during intensity-modulated radiotherapy in head and neck cancer: parotid glands

verfasst von: A. Fiorentino, M. Cozzolino, R. Caivano, P. Pedicini, C. Chiumento, C. Oliviero, S. Clemente, V. Fusco

Erschienen in: Clinical and Translational Oncology | Ausgabe 5/2013

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To evaluate the dosimetric changes of parotid glands (PG) during a course of intensity-modulated radiotherapy (IMRT) in head and neck (H&N) cancer patients.

Methods

Ten patients with H&N cancer treated by IMRT were analyzed. The original treatment plan (CTplan) was transferred to cone-beam computed tomography (CBCT) acquired at the 15th and 20th treatment day (CBCTplan I and II, respectively). The PG mean dose (D mean), the dose to 50 % of the volume, and the percent of volume receiving 30 and 50 Gy were measured by the dose volume histogram.

Results

30 IMRT plans were evaluated (3 plans/patient). All dosimetric end points increased significantly for both PG only when CTplan was compared to CBCTplan I. The D mean increased significantly only for ipsilateral PG (p = 0.02) at week 3.

Conclusion

During a course of IMRT, CBCT is a feasible method to check the PG dosimetric variations. Perhaps, the 3rd week of radiotherapy could be considered as the time-check-point.
Literatur
1.
Zurück zum Zitat Saarilahti K, Kouri M, Collan J et al (2006) Sparing of submandibular glands by intensity modulated radiotherapy in the treatment of head and neck cancer. Radiother Oncol 78:270–275PubMedCrossRef Saarilahti K, Kouri M, Collan J et al (2006) Sparing of submandibular glands by intensity modulated radiotherapy in the treatment of head and neck cancer. Radiother Oncol 78:270–275PubMedCrossRef
2.
Zurück zum Zitat Robar JL, Day A, Clancey J et al (2007) Spatial and dosimetric variability of organs at risk in head-and-neck intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys 68:1121–1130PubMedCrossRef Robar JL, Day A, Clancey J et al (2007) Spatial and dosimetric variability of organs at risk in head-and-neck intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys 68:1121–1130PubMedCrossRef
3.
4.
Zurück zum Zitat Barker JL Jr, Garden AS, Ang KK et al (2004) Quantification of volumetric and geometric changes occurring during fractionated radiotherapy for head-and-neck cancer using an integrated CT/linear accelerator system. Int J Radiat Oncol Biol Phys 59:960–970PubMedCrossRef Barker JL Jr, Garden AS, Ang KK et al (2004) Quantification of volumetric and geometric changes occurring during fractionated radiotherapy for head-and-neck cancer using an integrated CT/linear accelerator system. Int J Radiat Oncol Biol Phys 59:960–970PubMedCrossRef
5.
Zurück zum Zitat Lee C, Langen KM, Lu W et al (2008) Assessment of parotid gland dose changes during head and neck cancer radiotherapy using daily megavoltage computed tomography and deformable image registration. Int J Radiat Oncol Biol Phys 71:1563–1571PubMedCrossRef Lee C, Langen KM, Lu W et al (2008) Assessment of parotid gland dose changes during head and neck cancer radiotherapy using daily megavoltage computed tomography and deformable image registration. Int J Radiat Oncol Biol Phys 71:1563–1571PubMedCrossRef
6.
Zurück zum Zitat Han C, Chen YJ, Liu A, Schultheiss TE, Wong JY (2008) Actual dose variation of parotid glands and spinal cord for nasopharyngeal cancer patients during radiotherapy. Int J Radiat Oncol Biol Phys 70:1256–1262PubMedCrossRef Han C, Chen YJ, Liu A, Schultheiss TE, Wong JY (2008) Actual dose variation of parotid glands and spinal cord for nasopharyngeal cancer patients during radiotherapy. Int J Radiat Oncol Biol Phys 70:1256–1262PubMedCrossRef
7.
Zurück zum Zitat Hansen EK, Bucci MK, Quivey JM, Weinberg V, Xia P (2006) Repeat CT imaging and replanning during the course of IMRT for head-and-neck cancer. Int J Radiat Oncol Biol Phys 64:355–362PubMedCrossRef Hansen EK, Bucci MK, Quivey JM, Weinberg V, Xia P (2006) Repeat CT imaging and replanning during the course of IMRT for head-and-neck cancer. Int J Radiat Oncol Biol Phys 64:355–362PubMedCrossRef
8.
Zurück zum Zitat Ballivy O, Parker W, Vuong T, Shenouda G, Patrocinio H (2006) Impact of geometric uncertainties on the dose distribution during intensity modulated radiotherapy (IMRT) of head and neck cancer: the need for planning target volume (PTV) and planning organ at risk volume (PRV). Curr Oncol 13:108–115PubMed Ballivy O, Parker W, Vuong T, Shenouda G, Patrocinio H (2006) Impact of geometric uncertainties on the dose distribution during intensity modulated radiotherapy (IMRT) of head and neck cancer: the need for planning target volume (PTV) and planning organ at risk volume (PRV). Curr Oncol 13:108–115PubMed
9.
Zurück zum Zitat Wu Q, Chi Y, Chen PY, Krauss DJ, Yan D, Martinez A (2009) Adaptive replanning strategies accounting for shrinkage in head and neck IMRT. Int J Radiat Oncol Biol Phys 75:924–932PubMedCrossRef Wu Q, Chi Y, Chen PY, Krauss DJ, Yan D, Martinez A (2009) Adaptive replanning strategies accounting for shrinkage in head and neck IMRT. Int J Radiat Oncol Biol Phys 75:924–932PubMedCrossRef
10.
Zurück zum Zitat Zhao L, Wan Q, Zhou Y, Deng X, Xie C, Wu S (2011) The role of replanning in fractionated intensity modulated radiotherapy for nasopharyngeal carcinoma. Radiother Oncol 98:23–27PubMedCrossRef Zhao L, Wan Q, Zhou Y, Deng X, Xie C, Wu S (2011) The role of replanning in fractionated intensity modulated radiotherapy for nasopharyngeal carcinoma. Radiother Oncol 98:23–27PubMedCrossRef
11.
Zurück zum Zitat Bhide SA, Davies M, Burke K et al (2010) Weekly volume and dosimetric changes during chemoradiotherapy with intensity modulated radiation therapy for head and neck cancer: a prospective observational study. Int J Radiat Oncol Biol Phys 76(5):1360–1368PubMedCrossRef Bhide SA, Davies M, Burke K et al (2010) Weekly volume and dosimetric changes during chemoradiotherapy with intensity modulated radiation therapy for head and neck cancer: a prospective observational study. Int J Radiat Oncol Biol Phys 76(5):1360–1368PubMedCrossRef
12.
Zurück zum Zitat Nishimura Y, Nakamatsu K, Shibata T et al (2005) Importance of the initial volume of parotid glands in xerostomia for patients with head and neck cancer treated with IMRT. Jpn J Clin Oncol 35:375–379PubMedCrossRef Nishimura Y, Nakamatsu K, Shibata T et al (2005) Importance of the initial volume of parotid glands in xerostomia for patients with head and neck cancer treated with IMRT. Jpn J Clin Oncol 35:375–379PubMedCrossRef
13.
Zurück zum Zitat Ricchetti F, Wu B, McNutt T et al (2011) Volumetric change of selected organs at risk during IMRT for oropharyngeal cancer. Int J Radiat Oncol Biol Phys 80:161–168PubMedCrossRef Ricchetti F, Wu B, McNutt T et al (2011) Volumetric change of selected organs at risk during IMRT for oropharyngeal cancer. Int J Radiat Oncol Biol Phys 80:161–168PubMedCrossRef
14.
Zurück zum Zitat Vásquez Osorio EM, Hoogeman MS, Al-Mamgani A, Teguh DN, Levendag PC, Heijmen BJ (2008) Local anatomical changes in parotid and submandibular glands during radiotherapy for oropharynx cancer and correction with dose, studied in detail with non-rigid registration. Int J Radiat Oncol Biol Phys 70:875–882PubMedCrossRef Vásquez Osorio EM, Hoogeman MS, Al-Mamgani A, Teguh DN, Levendag PC, Heijmen BJ (2008) Local anatomical changes in parotid and submandibular glands during radiotherapy for oropharynx cancer and correction with dose, studied in detail with non-rigid registration. Int J Radiat Oncol Biol Phys 70:875–882PubMedCrossRef
15.
Zurück zum Zitat Ding GX, Munro P, Pawlowski J, Malcom A, Coffey CW (2010) Reducing radiation exposure to patients from Kv-CBCT imaging. Radiother Oncol 97(3):585–592PubMedCrossRef Ding GX, Munro P, Pawlowski J, Malcom A, Coffey CW (2010) Reducing radiation exposure to patients from Kv-CBCT imaging. Radiother Oncol 97(3):585–592PubMedCrossRef
16.
Zurück zum Zitat Pow EH, Kwong DL, McMillan AS et al (2006) Xerostomia and quality of life after intensity-modulated radiotherapy vs. conventional radiotherapy for early-stage nasopharyngeal carcinoma: initial report on a randomized controlled clinical trial. Int J Radiat Oncol Biol Phys 66(4):981–991PubMedCrossRef Pow EH, Kwong DL, McMillan AS et al (2006) Xerostomia and quality of life after intensity-modulated radiotherapy vs. conventional radiotherapy for early-stage nasopharyngeal carcinoma: initial report on a randomized controlled clinical trial. Int J Radiat Oncol Biol Phys 66(4):981–991PubMedCrossRef
17.
Zurück zum Zitat Donovan E, Bleakley N, Denholm E, Breast Technology Group et al (2007) Randomised trial of standard 2D radiotherapy (RT) versus intensity modulated radiotherapy (IMRT) in patients prescribed breast radiotherapy. Radiother Oncol 82(3):254–264PubMedCrossRef Donovan E, Bleakley N, Denholm E, Breast Technology Group et al (2007) Randomised trial of standard 2D radiotherapy (RT) versus intensity modulated radiotherapy (IMRT) in patients prescribed breast radiotherapy. Radiother Oncol 82(3):254–264PubMedCrossRef
18.
Zurück zum Zitat Ballivy O, Galiana Santamaría R, Lozano Borbalas A, Guedea Edo F (2008) Clinical application of intensity modulated radiotherapy for head and neck cancer. Clin Transl Oncol 10(7):407–414PubMedCrossRef Ballivy O, Galiana Santamaría R, Lozano Borbalas A, Guedea Edo F (2008) Clinical application of intensity modulated radiotherapy for head and neck cancer. Clin Transl Oncol 10(7):407–414PubMedCrossRef
19.
Zurück zum Zitat Loo H, Fairfoul J, Chakrabarti A et al (2011) Tumor shrinkage and contour change during radiotherapy increase the dose to organs at risk but not the target volumes for head and neck cancer patients treated on the tomotherapy HiArtTM system. Clin Oncol 23:40–47CrossRef Loo H, Fairfoul J, Chakrabarti A et al (2011) Tumor shrinkage and contour change during radiotherapy increase the dose to organs at risk but not the target volumes for head and neck cancer patients treated on the tomotherapy HiArtTM system. Clin Oncol 23:40–47CrossRef
20.
Zurück zum Zitat Castadot P, Geets X, Lee JA, Gregoire V (2011) Adaptive functional image guided IMRT in pharyngo-laryngeal squamous cell carcinoma: is the gain in dose distribution worth the effort? Radiother Oncol 101:343–350PubMedCrossRef Castadot P, Geets X, Lee JA, Gregoire V (2011) Adaptive functional image guided IMRT in pharyngo-laryngeal squamous cell carcinoma: is the gain in dose distribution worth the effort? Radiother Oncol 101:343–350PubMedCrossRef
21.
Zurück zum Zitat Lee L, Le QT, Xing L (2008) Retrospective IMRT dose reconstruction based on cone-beam CT and MLC log-file. Int J Radiat Oncol Biol Phys 70(2):634–644PubMedCrossRef Lee L, Le QT, Xing L (2008) Retrospective IMRT dose reconstruction based on cone-beam CT and MLC log-file. Int J Radiat Oncol Biol Phys 70(2):634–644PubMedCrossRef
22.
Zurück zum Zitat Too S, Yin FF (2006) Dosimetric feasibility of cone-beam CT-based treatment planning compared to CT-based treatment planning. Int J Radiat Oncol Biol Phys 66(5):1553–1561CrossRef Too S, Yin FF (2006) Dosimetric feasibility of cone-beam CT-based treatment planning compared to CT-based treatment planning. Int J Radiat Oncol Biol Phys 66(5):1553–1561CrossRef
23.
Zurück zum Zitat Ho FK, Marchant T, Moore C et al (2012) Monitoring dosimetric impact of weight loss with kilovoltage (KV) cone beam CT (CBCT) during parotid-sparing IMRT and concurrent chemotherapy. Int J Radiat Oncol Biol Phys 82(3):e375–e382PubMedCrossRef Ho FK, Marchant T, Moore C et al (2012) Monitoring dosimetric impact of weight loss with kilovoltage (KV) cone beam CT (CBCT) during parotid-sparing IMRT and concurrent chemotherapy. Int J Radiat Oncol Biol Phys 82(3):e375–e382PubMedCrossRef
Metadaten
Titel
Cone-beam computed tomography dose monitoring during intensity-modulated radiotherapy in head and neck cancer: parotid glands
verfasst von
A. Fiorentino
M. Cozzolino
R. Caivano
P. Pedicini
C. Chiumento
C. Oliviero
S. Clemente
V. Fusco
Publikationsdatum
01.05.2013
Verlag
Springer Milan
Erschienen in
Clinical and Translational Oncology / Ausgabe 5/2013
Print ISSN: 1699-048X
Elektronische ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-012-0946-4

Weitere Artikel der Ausgabe 5/2013

Clinical and Translational Oncology 5/2013 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.